Having trouble accessing articles? Reset your cache.

Exelixis licenses programs to Bristol-Myers

Exelixis Inc. (NASDAQ:EXEL) granted Bristol-Myers Squibb Co. (NYSE:BMY) exclusive, worldwide rights to develop and commercialize preclinical small molecule G protein-coupled bile

Read the full 211 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE